Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 693 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Cancer in My Community: Providing Supportive Care in Serbia October 14, 2021 New Approach May Help People with Cancer Better Manage Depression, Pain,... May 14, 2024 Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer June 26, 2019 Adding Atezolizumab to First-Line Bevacizumab Plus Platinum Regimen Improves Survival in... December 12, 2023 Load more HOT NEWS Study Identifies Hundreds of Potential Targets for Cancer Drugs Circulating T Cell Characteristics Associated with Immune Checkpoint Inhibitors-Induced irAEs Mom Births Stillborn Baby But Never Anticipated Nurse’s Remark She Will... Improving Care for Underserved People With Cancer and Evaluating Delays in...
